StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report released on Monday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 12.1 %

Shares of BTX opened at $2.22 on Monday. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The company has a market cap of $130.59 million, a price-to-earnings ratio of -0.87 and a beta of 4.61. The company’s fifty day simple moving average is $2.18 and its 200 day simple moving average is $1.80.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.